Evidence map›Paper›PMID 40167439›Full record

Trial reportRadiology2025

Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression.

Hao Wu, Zheng Zhu, Jiahui Li, Caixin Qiu, Peng Xu, Kevin J Glaser, Matthew C Murphy, Sudhakar K Venkatesh, Usman Yaqoob, Rondell Graham and 9 more

Abstract readClinical Trial
In one paragraph

Trial report in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Imaging Evaluation for Steatotic Liver Disease.Korean journal of radiology · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Hao Wu *Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0009-0007-2278-057X
Zheng Zhu *Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-4605-9783
Jiahui LiDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-4889-0714
Caixin QiuDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0009-0003-3394-7890
Peng XuDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-3321-9602
Kevin J GlaserDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-7464-5042
Matthew C MurphyDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
Sudhakar K VenkateshDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-7514-1030
Usman YaqoobDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn.
Rondell GrahamDivision of Anatomic Pathology, Mayo Clinic, Rochester, Minn.
Taofic MounajjedDivision of Anatomic Pathology, Mayo Clinic, Rochester, Minn.
Armando ManducaDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0002-9411-5671
Christopher T WinkelmannTakeda Pharmaceutical, Cambridge, Mass.ORCID 0000-0001-8656-5069
Hiroaki YashiroTakeda Pharmaceutical, Cambridge, Mass.
Rohan ManoharTakeda Pharmaceutical, Cambridge, Mass.
Alina M AllenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn.
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minn.ORCID 0000-0001-7620-573X
Richard L EhmanDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0001-7041-5074
Meng YinDepartment of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.ORCID 0000-0001-6778-192X

Funding

PILOT AND FEASIBILTY PROGRAMP30DK084567 · NIDDK · MAYO CLINIC ROCHESTER · PI Nicholas F. LaRusso · 2009 to 2026
$22.2M
Molecular Mechanisms of Portal HypertensionR01DK059615 · NIDDK · MAYO CLINIC ROCHESTER · PI SHAH, VIJAY H. · 2002 to 2023
$6.4M
TREAT-MayoU01AA021788 · NIAAA · MAYO CLINIC ROCHESTER · PI MALHI, HARMEET, SHAH, VIJAY H. · 2012 to 2022
$4.7M
Comprehensive noninvasive assessment of liver histopathology in nonalcoholic fatty liver disease (NAFLD) via magnetic resonance imaging, cytometry and elastography (MR-ICE)R01EB017197 · NIBIB · MAYO CLINIC ROCHESTER · PI YIN, MENG · 2014 to 2025
$4.3M
Magnetic Resonance ElastographyR37EB001981 · NIBIB · MAYO CLINIC ROCHESTER · PI EHMAN, RICHARD L. · 2016 to 2025
$4.0M
Molecular Mechanisms of Liver Fibrosis (Diversity Supplement)R37AA021171 · NIAAA · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH · 2019 to 2026
$3.0M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD) – Mayo ClinicU01AA026974 · NIAAA · MAYO CLINIC ROCHESTER · PI VICTOR M. KARPYAK, VIJAY H. SHAH · 2018 to 2026
$2.9M
Liver Cirrhosis Network: Clinical Research Center - Mayo ClinicU01DK130181 · NIDDK · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH, Douglas A. Simonetto · 2021 to 2026
$1.9M
Advancing MR elastography to map mechanical signatures of key AD/ADRD processesR01AG076636 · NIA · MAYO CLINIC ROCHESTER · PI Matthew Christopher Murphy · 2023 to 2026
$1.8M
Quantitative characterization of the liver-pancreas axis in diabetes via multiparametric magnetic resonance elastographyR01DK136731 · NIDDK · MAYO CLINIC ROCHESTER · PI Meng Yin · 2023 to 2026
$1.6M
NAFLD Diagnosis and OutcomesR01DK134448 · NIDDK · MAYO CLINIC ROCHESTER · PI Alina M Allen · 2024 to 2026
$1.5M
Noninvasive assessment of portal hypertension and hepatic interstitial pressure with advanced magnetic resonance elastographyR01DK132718 · NIDDK · MAYO CLINIC ROCHESTER · PI Meng Yin · 2023 to 2026
$1.3M
NIAAA NIH HHS R37 AA021171NIAAA NIH HHS U01 AA021788NIAAA NIH HHS U01 AA026886NIAAA NIH HHS U01 AA026974NIAAA NIH HHS UH3 AA026887NIA NIH HHS R01 AG076636NIA NIH HHS R01 AG081584NIBIB NIH HHS R01 EB017197NIBIB NIH HHS R37 EB001981NIDDK NIH HHS K23 DK115594NIDDK NIH HHS P30 DK084567NIDDK NIH HHS R01 DK059615NIDDK NIH HHS R01 DK132718NIDDK NIH HHS R01 DK134448NIDDK NIH HHS R01 DK136731NIDDK NIH HHS U01 DK130181
6 · The paper itself

Abstract

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health challenge, with evidence indicating that hepatic inflammation and fibrosis are heterogeneous processes. Purpose To measure liver mechanical property heterogeneity using MR elastography (MRE) and evaluate its potential as a biomarker for tissue inflammation and fibrosis in patients with MASLD. Materials and Methods Mechanical tissue heterogeneity in MASLD was assessed at three-dimensional vector MRE pixel-wise histogram analysis of shear stiffness and loss modulus in preclinical and clinical studies. The preclinical study involved 25 rats that were examined monthly, whereas the clinical study analyzed data from 179 participants across two prospective studies (September 2015 to November 2022), including some who underwent bariatric surgery at pretreatment and posttreatment MRE examinations. Mean and coefficient of variation (CV) of shear stiffness and loss modulus were calculated for each examination. Nonparametric tests and Spearman correlation coefficient were used to compare MRE-derived tissue mechanics with biopsy-confirmed fibrosis and inflammation and assess correlations with portal pressure and histopathologic hepatic fibrosis. Results The preclinical study showed that, in cirrhotic livers, CV of loss modulus positively correlated with portal pressure and fibrosis area ratio variation (ρ = 0.52 [

Indexed as

Elasticity Imaging TechniquesImaging, Three-DimensionalMagnetic Resonance ImagingAdultAnimalsDisease ProgressionFemaleHumansLiverLiver CirrhosisMaleMiddle AgedProspective StudiesRats

Identifiers

PMID40167439
PMCPMC12784277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.